Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06618014 | Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)(NeoTOP) | active not recruiting | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06897488 | EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial | recruiting | Phase 2 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 |
| clinicaltrials |
| NCT07394387 | Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. | recruiting | Phase 2 | 58 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05085002 | A Study of Lerociclib in Participants With Advanced Breast Cancer | terminated | Phase 2 | 100 | EQRx, Inc.INDUSTRY | 6 | May 14, 2026 | clinicaltrials |
| NCT05296746 | Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer(RIBOLARIS) | active not recruiting | Phase 2 | 1,100 | SOLTI Breast Cancer Research GroupOTHER | 3 | May 14, 2026 | clinicaltrials |
| NCT06023576 | A Study of Blood Pressure Control During Cancer Treatment | recruiting | Phase 2 | 130 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07053085 | A Study of Surgery and Radiotherapy in People With Breast Cancer | recruiting | Phase 2 | 178 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07395336 | Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)(COMBINE-01) | recruiting | Phase 2 | 26 | European Institute of OncologyOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07586826 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors(N01-A-PICIT-GT) | recruiting | Phase 2 | 220 | Peking University People's HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05812924 | A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause | active not recruiting | Phase 2 | 18 | University of MiamiOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06844669 | HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy | terminated | Phase 2 | 7 | Washington University School of MedicineOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07283692 | Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | recruiting | Phase 2 | 46 | RenJi HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT00631852 | A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer | completed | Phase 2 | 16 | Southern Illinois UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT02689427 | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03609047 | Adjuvant Palbociclib in Elderly Patients With Breast Cancer(Appalaches) | active not recruiting | Phase 2 | 366 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | May 12, 2026 | clinicaltrials |
| NCT03941730 | Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer | active not recruiting | Phase 2 | 8 | Mayo ClinicOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07581795 | Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer(SPECTACLE) | not yet recruiting | Phase 2 | 140 | Fudan UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07581834 | Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study | recruiting | Phase 2 | 2,000 | Fujian Cancer HospitalOTHER_GOV | 1 | May 12, 2026 | clinicaltrials |
| NCT01621659 | Multidisciplinary Team IntervenTion in CArdio-ONcology (TITAN Study)(TITAN) | active not recruiting | Phase 2 | 80 | University of AlbertaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04505826 | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer | completed | Phase 1 / Phase 2 | 153 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | May 11, 2026 | clinicaltrials |
| NCT05319873 | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05498896 | Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC(BARBICAN) | active not recruiting | Phase 2 | 146 | Queen Mary University of LondonOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06048718 | T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases(TUXEDO-4) | active not recruiting | Phase 2 | 28 | MedSIROTHER | 2 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07258108 | Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors | recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04771871 | MicroRNA Profiles in Triple Negative Breast Cancer(TARMAC) | recruiting | Phase 2 | 42 | University College Hospital, IbadanOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05596409 | ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study(ELCIN) | active not recruiting | Phase 2 | 61 | Stemline Therapeutics, Inc.INDUSTRY | 6 | May 7, 2026 | clinicaltrials |
| NCT05601440 | Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer | recruiting | Phase 2 | 484 | Canadian Cancer Trials GroupNETWORK | 1 | May 7, 2026 | clinicaltrials |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer(I-SPY) | recruiting | Phase 2 | 5,000 | QuantumLeap Healthcare CollaborativeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03990896 | Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04268134 | Altering Lipids for Tolerance of Aromatase Inhibitor Therapy(ALTA) | completed | Phase 2 | 77 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04553133 | PF-07104091 as a Single Agent and in Combination Therapy | active not recruiting | Phase 2 | 157 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT04647916 | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases | active not recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT05591547 | Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen(APBI RISE) | active not recruiting | Phase 2 | 91 | Sanford HealthOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06125522 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | active not recruiting | Phase 1 / Phase 2 | 11 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06617455 | Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial(VEnT) | terminated | Phase 2 | 9 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06727773 | Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer | recruiting | Phase 2 | 90 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06845319 | NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients(NeoCARD) | recruiting | Phase 2 | 43 | Medical University of South CarolinaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07220135 | Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer(NeoTHERa) | recruiting | Phase 2 | 100 | University of Kansas Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT01670500 | Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa | completed | Phase 2 | 118 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05716516 | STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)(ESTHER) | recruiting | Phase 2 | 36 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07354919 | Axelopran for Advanced Cancer in Patients Receiving Opioids(AxeCan) | recruiting | Phase 2 | 34 | HealthPartners InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT04434040 | Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | recruiting | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05865990 | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease(TUXEDO-3) | completed | Phase 2 | 63 | MedSIROTHER | 2 | May 4, 2026 | clinicaltrials |
| NCT07565324 | Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)(UC HER) | not yet recruiting | Phase 2 | 54 | National Taiwan University HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT01245712 | Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer | active not recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07134556 | Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC(ADJUNCT) | withdrawn | Phase 2 | 0 | MedSIROTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT07285993 | Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET | not yet recruiting | Phase 2 | 15 | Randy YehOTHER | 1 | May 1, 2026 | clinicaltrials |
Data updated 24 days agoSource updated May 15, 2026source: clinicaltrials